Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials - PubMed

Novartis Pharma.
pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov